<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85772">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02044250</url>
  </required_header>
  <id_info>
    <org_study_id>HOST-EXAM Trial</org_study_id>
    <nct_id>NCT02044250</nct_id>
  </id_info>
  <brief_title>Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- EXtended Antiplatelet Monotherapy (HOST-EXAM)</brief_title>
  <official_title>Comparison of Clopidogrel vs. Aspirin Monotherapy Beyond Two Year After Drug-eluting Stent Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>SAMJIN PHARMACEUTICAL CO.,Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>HANMI PHARMA CO.,Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <authority>Republic of Korea : Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives :

      To compare the efficacy and safety of clopidogrel monotherapy with aspirin monotherapy in
      patients who received dual or triple antiplatelet therapy for 1 year (± 6 months) after
      drug-eluting stent implantation for coronary artery disease

      Patient Enrollment :

      5500 patients enrolled at 55 centers in Korea

      Patient Follow-up :

      Clinical follow-up will occur at 1, 12 and 24 months.

      Primary Endpoint :

      composite of cardiovasculr death, myocardial infarction, stroke, severe/moderate bleeding,
      readmission due to acute coronary syndrome, urgent revascularization

      Secondary Endpoint :

      Target vessel/lesion revascularization Stent thrombosis (acute, sub-acute, late, very late)
      Peripheral vascular intervention
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Composite of adverse cardiovascular outcomes</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>composite of cardiovasculr death, myocardial infarction, stroke, severe/moderate bleeding, readmission due to acute coronary syndrome, urgent revascularization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target vessel/lesion revascularization</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis (acute, sub-acute, late, very late)</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral vascular intervention</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">5500</enrollment>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Antiplatelet monotheraphy : Clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Antiplatelet monotheraphy : Aspirin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel (Copregrel / Plateless / Cloart / Pidogul)</intervention_name>
    <arm_group_label>Clopidogrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <arm_group_label>Aspirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must be at least 20 years of age.

          2. Subject who received dual or triple antiplatelet therapy for 1 year (± 6 months)
             after drug-eluting stent implantation for coronary artery disease

          3. Subject without clinical events during 1 year (± 6 months)

          4. Subject who is confirmed to receive antiplatelet monotherapy (aspirin or clopidogrel)

          5. Subject is able to verbally confirm understandings of risks, benefits and treatment
             and he/she or his/her legally authorized representative provides written informed
             consent prior to any study related procedure.

          6. Subject is fertile woman and able to verbally confirm using effective methods of
             contraception

        Exclusion Criteria:

          1. The patient has a known hypersensitivity or contraindication to aspirin or
             clopidogrel.

          2. Subject who cannot interrupt to receive antiplatelet drug.

          3. History of bleeding diathesis or known coagulopathy requiring interruption of
             antiplatelet drugs.

          4. An elective intervention or surgical procedure is planned that would necessitate
             long-term interruption of antiplatelet drugs during the study.

          5. Liver function abnormality or renal failure

               -  AST, ALT &gt; 3 x UNL

               -  Creatinine &gt; 2.0 mg/dL

          6. Non-cardiac co-morbid conditions are present with life expectancy &lt; 2 years.

          7. Subject who is pregnant, breastfeeding.

          8. Subject who is not suitable to enroll the study decided by investigator
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyo-Soo Kim, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bon-Kwon Koo, MD, PhD</last_name>
    <phone>82-2-2072-2062</phone>
    <email>bkkoo@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hyo-Soo Kim, MD, PhD</last_name>
    <phone>82-2-2072-2226</phone>
    <email>hyosoo@snu.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bon-Kwon Koo, MD, PhD</last_name>
      <phone>82-2-2072-2062</phone>
      <email>bkkoo@snu.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Hyo-Soo Kim, MD, PhD</last_name>
      <phone>82-2-2072-2226</phone>
      <email>hyosoo@snu.ac.kr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 22, 2014</lastchanged_date>
  <firstreceived_date>January 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aspirin</keyword>
  <keyword>Clopidogrel</keyword>
  <keyword>Antiplatelet monotherapy</keyword>
  <keyword>Drug-eluting stent</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
